Cargando…
A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs)
BACKGROUND: There is a clinical need for point-of-care (POC) methods for non-vitamin K-dependent oral anticoagulants (NOACs). We modified a routine POC procedure: Zafena’s Simple Simon™ PT-INR, a room-temperature, wet-chemistry prothrombin time method of the Owren-type. METHODS: To either increase o...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649322/ https://www.ncbi.nlm.nih.gov/pubmed/28891412 http://dx.doi.org/10.1080/03009734.2017.1370040 |
_version_ | 1783272532867022848 |
---|---|
author | Lindahl, Tomas L. Arbring, Kerstin Wallstedt, Maria Rånby, Mats |
author_facet | Lindahl, Tomas L. Arbring, Kerstin Wallstedt, Maria Rånby, Mats |
author_sort | Lindahl, Tomas L. |
collection | PubMed |
description | BACKGROUND: There is a clinical need for point-of-care (POC) methods for non-vitamin K-dependent oral anticoagulants (NOACs). We modified a routine POC procedure: Zafena’s Simple Simon™ PT-INR, a room-temperature, wet-chemistry prothrombin time method of the Owren-type. METHODS: To either increase or decrease NOAC interference, two assay variants were devised by replacing the standard 10 µL end-to-end capillary used to add the citrated plasma sample to 200 µL of prothrombin time (PT) reagent by either a 20 µL or a 5 µL capillary. All assay variants were calibrated to show correct PT results in plasma samples from healthy and warfarin-treated persons. RESULTS: For plasmas spiked with dabigatran, apixaban, or rivaroxaban, the 20 µL variant showed markedly higher PT results than the 5 µL. The effects were even more pronounced at room temperature than at +37 °C. In plasmas from patients treated with NOACs (n = 30 for each) there was a strong correlation between the PT results and the concentration of NOACs as determined by the central hospital laboratory. For the 20 µL variant the PT response of linear correlation coefficient averaged 0.90. The PT range was INR 1.1–2.1 for dabigatran and apixaban, and INR 1.1–5.0 for rivaroxaban. Using an INR ratio between the 20 µL and 5 µL variants (PTr20/5) made the NOAC assay more robust and independent of the patient sample INR value in the absence of NOAC. Detection limits were 80 µg/L for apixaban, 60 µg/L for dabigatran, and 20 µg/L for rivaroxaban. CONCLUSIONS: A wet-chemistry POC PT procedure was modified to measure the concentrations of three NOACs using a single reagent. |
format | Online Article Text |
id | pubmed-5649322 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-56493222017-10-27 A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs) Lindahl, Tomas L. Arbring, Kerstin Wallstedt, Maria Rånby, Mats Ups J Med Sci Original Articles BACKGROUND: There is a clinical need for point-of-care (POC) methods for non-vitamin K-dependent oral anticoagulants (NOACs). We modified a routine POC procedure: Zafena’s Simple Simon™ PT-INR, a room-temperature, wet-chemistry prothrombin time method of the Owren-type. METHODS: To either increase or decrease NOAC interference, two assay variants were devised by replacing the standard 10 µL end-to-end capillary used to add the citrated plasma sample to 200 µL of prothrombin time (PT) reagent by either a 20 µL or a 5 µL capillary. All assay variants were calibrated to show correct PT results in plasma samples from healthy and warfarin-treated persons. RESULTS: For plasmas spiked with dabigatran, apixaban, or rivaroxaban, the 20 µL variant showed markedly higher PT results than the 5 µL. The effects were even more pronounced at room temperature than at +37 °C. In plasmas from patients treated with NOACs (n = 30 for each) there was a strong correlation between the PT results and the concentration of NOACs as determined by the central hospital laboratory. For the 20 µL variant the PT response of linear correlation coefficient averaged 0.90. The PT range was INR 1.1–2.1 for dabigatran and apixaban, and INR 1.1–5.0 for rivaroxaban. Using an INR ratio between the 20 µL and 5 µL variants (PTr20/5) made the NOAC assay more robust and independent of the patient sample INR value in the absence of NOAC. Detection limits were 80 µg/L for apixaban, 60 µg/L for dabigatran, and 20 µg/L for rivaroxaban. CONCLUSIONS: A wet-chemistry POC PT procedure was modified to measure the concentrations of three NOACs using a single reagent. Taylor & Francis 2017-08 2017-09-11 /pmc/articles/PMC5649322/ /pubmed/28891412 http://dx.doi.org/10.1080/03009734.2017.1370040 Text en © 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Lindahl, Tomas L. Arbring, Kerstin Wallstedt, Maria Rånby, Mats A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs) |
title | A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs) |
title_full | A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs) |
title_fullStr | A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs) |
title_full_unstemmed | A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs) |
title_short | A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs) |
title_sort | novel prothrombin time method to measure all non-vitamin k-dependent oral anticoagulants (noacs) |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649322/ https://www.ncbi.nlm.nih.gov/pubmed/28891412 http://dx.doi.org/10.1080/03009734.2017.1370040 |
work_keys_str_mv | AT lindahltomasl anovelprothrombintimemethodtomeasureallnonvitaminkdependentoralanticoagulantsnoacs AT arbringkerstin anovelprothrombintimemethodtomeasureallnonvitaminkdependentoralanticoagulantsnoacs AT wallstedtmaria anovelprothrombintimemethodtomeasureallnonvitaminkdependentoralanticoagulantsnoacs AT ranbymats anovelprothrombintimemethodtomeasureallnonvitaminkdependentoralanticoagulantsnoacs AT lindahltomasl novelprothrombintimemethodtomeasureallnonvitaminkdependentoralanticoagulantsnoacs AT arbringkerstin novelprothrombintimemethodtomeasureallnonvitaminkdependentoralanticoagulantsnoacs AT wallstedtmaria novelprothrombintimemethodtomeasureallnonvitaminkdependentoralanticoagulantsnoacs AT ranbymats novelprothrombintimemethodtomeasureallnonvitaminkdependentoralanticoagulantsnoacs |